Salbutamol in the management of asthma: A review
L Marques, N Vale - International Journal of Molecular Sciences, 2022 - mdpi.com
Asthma is a common inflammatory disease of the lungs. The prevalence of asthma is
increasing worldwide, and the tendency indicates that the number of asthma sufferers will …
increasing worldwide, and the tendency indicates that the number of asthma sufferers will …
Albuterol–budesonide fixed-dose combination rescue inhaler for asthma
A Papi, BE Chipps, R Beasley… - … England Journal of …, 2022 - Mass Medical Soc
Background As asthma symptoms worsen, patients typically rely on short-acting β2-agonist
(SABA) rescue therapy, but SABAs do not address worsening inflammation, which leaves …
(SABA) rescue therapy, but SABAs do not address worsening inflammation, which leaves …
[HTML][HTML] Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised …
Background Stepwise intensification of inhaled corticosteroids (ICS) is routine for severe
eosinophilic asthma, despite some poor responses to high-dose ICS. Dose reductions are …
eosinophilic asthma, despite some poor responses to high-dose ICS. Dose reductions are …
A charter to fundamentally change the role of oral corticosteroids in the management of asthma
J Haughney, T Winders, S Holmes, P Chanez… - Advances in …, 2023 - Springer
Asthma affects 339 million people worldwide, with an estimated 5–10% experiencing severe
asthma. In emergency settings, oral corticosteroids (OCS) can be lifesaving, but acute and …
asthma. In emergency settings, oral corticosteroids (OCS) can be lifesaving, but acute and …
Observational UK cohort study to describe intermittent oral corticosteroid prescribing patterns and their association with adverse outcomes in asthma
Introduction Oral corticosteroids (OCS) for asthma are associated with increased risks of
develo** adverse outcomes (adverse outcomes); no previous study has focused …
develo** adverse outcomes (adverse outcomes); no previous study has focused …
Over-prescription of short-acting β2-agonists is associated with poor asthma outcomes: results from the Latin American cohort of the SABINA III study
F Montero-Arias, JCH Garcia, MP Gallego… - Journal of …, 2023 - Taylor & Francis
Objective Short-acting β2-agonist (SABA) over-reliance is associated with poor asthma
outcomes. As part of the SABA Use IN Asthma (SABINA) III study, we assessed SABA …
outcomes. As part of the SABA Use IN Asthma (SABINA) III study, we assessed SABA …
The carbon footprint of respiratory treatments in Europe and Canada: an observational study from the CARBON programme
Climate change represents a global challenge and nations are increasingly looking to
decarbonise their economies by develo** roadmaps for reducing greenhouse gas (GHG) …
decarbonise their economies by develo** roadmaps for reducing greenhouse gas (GHG) …
[HTML][HTML] SABA use as an indicator for asthma exacerbation risk: an observational cohort study (SABINA Canada)
SG Noorduyn, C Qian, KM Johnston… - ERJ Open …, 2022 - Eur Respiratory Soc
Background Patients with asthma use short-acting β-agonists (SABA) to relieve symptoms
but SABA alone does not treat underlying inflammation. Thus, over-reliance on SABA may …
but SABA alone does not treat underlying inflammation. Thus, over-reliance on SABA may …
Landscape of short‐acting beta‐agonists (SABA) overuse in Europe
This review article provides an overview of short‐acting beta‐agonist (SABA) use and
prescribing trends in Europe, summarizing updated data on the results from the industry …
prescribing trends in Europe, summarizing updated data on the results from the industry …
[HTML][HTML] Short-acting β2-agonists (SABA) overuse in asthma and patients' perceptions for this behavior
CD Visser, MRA Faay, A Özdemir, HJ Guchelaar… - Respiratory …, 2024 - Elsevier
Background Short-acting β 2-agonists (SABA) overuse is associated with poor asthma
control. The Global Initiative for Asthma (GINA) 2019-updated strategy report has therefore …
control. The Global Initiative for Asthma (GINA) 2019-updated strategy report has therefore …